

Subpar movie slate drags down performance

Media & Entertainment ▶ Result Update ▶ July 22, 2024

TARGET PRICE (Rs): 1,650

PVR Inox's results reflect the subpar box-office collections during the quarter due to a weak slate of movie-lineup, given the general elections happening over an extended period, and the IPL and T20 World Cup held during Q1. Footfalls fell further to 30.4mn, down 6.7% QoQ, whereas ATP inched up marginally to Rs235 from Rs233 in Q4 albeit still impacted by the lack of big-budget releases and higher promotional offers. Occupancy was weak at 20.6%. Select small-to-mid-budget movies did see some traction, though not enough to move the needle. The management is taking steps to drive higher revenue and to optimize costs, but these are likely to fructify only in the medium term. The near-term movie pipeline has improved which should result in some pick-up in collections going ahead. We cut FY25E/26E EBITDA by 9%/2%, to factor in the Q1 performance; also, we introduce FY27 estimates. We maintain BUY on the stock, with unchanged TP of Rs1,650/sh (roll-over to Jun-26E pre-IndAS EBITDA).

PVR INOX: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	37,507	61,071	64,478	75,832	83,968
EBITDA	10,473	18,101	20,333	26,490	29,177
Adj. PAT	(3,273)	(334)	1,135	5,317	6,557
Adj. EPS (Rs)	(52.0)	(3.4)	11.6	54.3	66.9
EBITDA margin (%)	27.9	29.6	31.5	34.9	34.7
EBITDA growth (%)	890.4	72.8	12.3	30.3	10.1
Adj. EPS growth (%)	0.0	0.0	0.0	368.4	23.3
RoE (%)	(7.5)	(0.5)	1.5	6.9	7.9
RoIC (%)	5.0	3.1	4.9	6.7	7.2
P/E (x)	(28.3)	(418.3)	123.1	26.3	21.3
EV/EBITDA (x)	16.2	12.1	10.9	8.2	7.4
P/B (x)	1.3	1.9	1.9	1.8	1.6
FCFF yield (%)	1.4	6.2	2.6	5.1	4.4

Source: Company, Emkay Research

Results Summary

Revenue declined 5.2% QoQ to Rs11.9bn, broadly in line with our estimates. ATP improved marginally to Rs235 from Rs233 in Q4FY24, but is still trending at lower levels due to lack of big-budget films and given promotional offers. Also, SPH improved to Rs134 from Rs129 in Q4FY24. Occupancy declined to 20.3% from 22.6% in Q4, while Admits fell 6.7% QoQ to 30.4mn. Advertisement revenue also declined 10.6% QoQ to Rs0.9bn, owing to inconsistent performance of movies. Reported EBITDA declined 9.7% QoQ to Rs2.5bn – higher than our estimate. Adjusted for IndAS, EBITDA loss was Rs327mn. The company reported net loss of Rs1.8bn. The multiplex chain opened 50 screens in the quarter, while shutting down another 14. It is on track to open 120 screens in FY25 and shut 50-60. Gross debt decreased, from Rs17.2bn to Rs16.9bn, whereas net debt inched up, from Rs12.9bn to Rs13.2bn.

Earnings Call KTAs

1) Quarterly Results: The quarterly performance was hit by the 2024 General Elections, with 13% drop in the number of releases (YoY) and only 3 movies crossing the Rs1-billion mark. In this quarter, 1.25mn admits were from re-release of movies. 2) ATP: The company has always followed the flexi pricing model. It did increase ticket prices by 4% YoY, to pass on the higher inflation to customers, but given lack of blockbuster movies, reported ATP was lower. Beginning-Q2 has seen strong growth in ATP. 3) Pipeline: The management does not see any more external events hampering the pipeline. The CY25/FY26 content pipeline should be back to pre-Covid levels, with Q3FY25 expected to be the strongest quarter in the year. 4) Passport Program: The company has already sold 0.25mn passes, and expects a pickup as the content pipeline improves. 5) OTT Window period: The general viewpoint across stakeholders is that the OTT window period should be common across languages. 6) JV with Devyani International: This JV has already been set up, with 2 food courts expected to be operational in coming 2-3 months, and 4-5 courts expected to be operational by FY25-end. 7) Media reports on additional cess in Karnataka: There is no confirmation that this is a definitive order. If the cess were to be imposed, it would be detrimental for the industry. 8) Expenses: Like-to-like rentals have increased 3.7% YoY, in line with lease agreements, with total fixed costs rising 7% YoY; of this, 4-4.5% cost is on account of new cinemas opened last year.

Target Price – 12M	Jun-25
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	15.7
CMP (22-Jul-24) (Rs)	1,426.0

Stock Data	Ticker
52-week High (Rs)	1,880
52-week Low (Rs)	1,204
Shares outstanding (mn)	98.1
Market-cap (Rs bn)	140
Market-cap (US\$ mn)	1,673
Net-debt, FY25E (Rs mn)	81,176
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	920.3
ADTV-3M (US\$ mn)	11.0
Free float (%)	72.5
Nifty-50	24,509
INR/US\$	83.7
Shareholding, Jun-24	
Promoters (%)	27.8
FPIs/MFs (%)	18.1/38.8

Price Performance

(%)	1M	3M	12M
Absolute	(0.8)	(0.5)	(5.2)
Rel. to Nifty	(4.8)	(9.3)	(23.6)

1-Year share price trend (Rs)



Pulkit Chawla

pulkit.chawla@emkayglobal.com
+91 22 6624 2458

Exhibit 1: Actual vs Estimates (Q1FY25)

(Rs mn)	Actual	Estimate		% variation		Comment
		Emkay	Consensus	Emkay	Consensus	
Revenue	11,907	11,974	13,037	-1%	-9%	Broadly in line with our estimates
EBITDA	2,515	2,193	2,836	15%	-11%	Aided by lower than expected film exhibition and employee expenses
EBITDA margin	21.1%	18.3%	21.8%	281 bps	-63 bps	
PAT	-1,787	-1,743	-1,692	3%	6%	

Source: Company, Emkay Research

Exhibit 2: Quarterly financial snapshot

(Rs mn)	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	YoY (%)	QoQ (%)
Net Sales	13,049	19,999	15,459	12,564	11,907	-8.8	-5.2
Film exhibition cost	2980	4954	3710	2469	2451	-17.8	-0.7
as % of sales	22.8	24.8	24.0	19.7	20.6		
Cost of materials consumed	1071	1544	1248	1131	1005	-6.2	-11.1
as % of sales	8.2	7.7	8.1	9.0	8.4		
Employee costs	1559	1679	1629	1706	1643	5.4	-3.7
as % of sales	11.9	8.4	10.5	13.6	13.8		
Repairs & maintenance	3914	4754	4148	4474	4293	9.7	-4.0
as % of sales	30.0	23.8	26.8	35.6	36.1		
Total Expenditure	9,524	12,931	10,735	9,780	9,392	-1.4	-4.0
EBITDA	3,525	7,068	4,724	2,784	2,515	-28.7	-9.7
Depreciation	2,908	3,086	3,171	3,028	3,142	8.0	3.8
EBIT	617	3,982	1,553	(244)	(627)	-201.6	157.0
Other Income	249	238	588	491	287	15.3	-41.5
Interest	1,945	2,003	1,966	1,999	2,041	4.9	2.1
Exceptional item	-	-	-	-	-		
PBT	(1,079)	2,217	175	(1,752)	(2,381)	120.7	35.9
Tax	(259)	555	47	(455)	(591)	128.2	29.9
PAT before MI	(820)	1,662	128	(1,297)	(1,790)	118.3	38.0
Minority interest	(4)	(1)	(2)	(2)	(3)	-25.0	71.4
PAT	(816)	1,663	130	(1,295)	(1,787)	119.0	38.0
(%)						(bps)	(bps)
EBITDAM	27.0	35.3	30.6	22.2	21.1	-589	-104
EBITM	4.7	19.9	10.0	-1.9	-5.3	-999	-332
PBTM	-8.3	11.1	1.1	-13.9	-20.0	-1,173	-605
PATM	-6.3	8.3	0.8	-10.3	-15.0	-875	-470
Effective Tax rate	24.0	25.0	26.9	26.0	24.8	82	-115

Source: Company, Emkay Research

Exhibit 3: Change in estimates

(Rs mn)	FY25E			FY26E			FY27E
	Old	New	% Change	Old	New	% Change	Introduced
Revenue	66,976	64,478	-3.7	77,785	75,832	-2.5	83,968
EBITDA	22,478	20,333	-9.5	26,975	26,490	-1.8	29,177
EBITDA Margin (%)	33.6	31.5	-207 bps	34.7	34.9	23 bps	34.7
EBITDA (Adj. for IndAS)	11,169	9,021	-19.2	15,213	14,687	-3.5	17,138
PAT	2,510	1,135	-54.8	5,628	5,317	-5.5	6,557
EPS (Rs)	25.6	11.6	-54.7	57.4	54.3	-5.5	66.9

Source: Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/11/2024 05:34 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

PVR INOX: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	37,507	61,071	64,478	75,832	83,968
Revenue growth (%)	181.8	62.8	5.6	17.6	10.7
EBITDA	10,473	18,101	20,333	26,490	29,177
EBITDA growth (%)	890.4	72.8	12.3	30.3	10.1
Depreciation & Amortization	7,533	12,193	12,700	13,200	14,500
EBIT	2,940	5,908	7,633	13,290	14,677
EBIT growth (%)	0.0	101.0	29.2	74.1	10.4
Other operating income	0	0	0	0	0
Other income	791	1,566	1,600	1,700	1,900
Financial expense	5,716	7,913	8,025	7,885	7,815
PBT	(1,986)	(439)	1,208	7,105	8,763
Extraordinary items	(108)	0	0	0	0
Taxes	1,274	(112)	73	1,788	2,206
Minority interest	13	7	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	(3,381)	(334)	1,135	5,317	6,557
PAT growth (%)	0.0	0.0	0.0	368.4	23.3
Adjusted PAT	(3,273)	(334)	1,135	5,317	6,557
Diluted EPS (Rs)	(52.0)	(3.4)	11.6	54.3	66.9
Diluted EPS growth (%)	0.0	0.0	0.0	368.4	23.3
DPS (Rs)	0.0	0.0	0.0	0.0	0.0
Dividend payout (%)	0.0	0.0	0.0	0.0	0.0
EBITDA margin (%)	27.9	29.6	31.5	34.9	34.7
EBIT margin (%)	7.8	9.7	11.8	17.5	17.5
Effective tax rate (%)	(64.2)	25.5	6.0	25.2	25.2
NOPLAT (pre-IndAS)	4,826	4,401	7,171	9,945	10,983
Shares outstanding (mn)	65.0	98.0	98.0	98.0	98.0

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
PBT	(1,986)	(439)	1,208	7,105	8,763
Others (non-cash items)	12,589	19,013	8,025	7,885	7,815
Taxes paid	1	326	(73)	(1,788)	(2,206)
Change in NWC	(1,969)	890	1,509	2,212	(979)
Operating cash flow	8,635	19,790	10,669	15,413	13,392
Capital expenditure	(6,339)	(6,269)	(4,822)	(4,236)	(3,980)
Acquisition of business	0	0	0	0	0
Interest & dividend income	88	17	0	0	0
Investing cash flow	(5,759)	(6,266)	(4,822)	(4,236)	(3,980)
Equity raised/(repaid)	305	188	0	0	0
Debt raised/(repaid)	1,260	(732)	(1,000)	(1,000)	(1,000)
Payment of lease liabilities	(7,059)	(10,589)	659	1,330	1,357
Interest paid	(1,442)	(1,792)	(8,025)	(7,885)	(7,815)
Dividend paid (incl tax)	0	0	0	0	0
Others	301	108	108	108	108
Financing cash flow	(6,634)	(12,817)	(8,259)	(7,446)	(7,350)
Net chg in Cash	(3,758)	707	(2,412)	3,731	2,063
OCF	8,635	19,790	10,669	15,413	13,392
Adj. OCF (w/o NWC chg.)	6,666	20,680	12,178	17,625	12,413
FCFF	2,296	13,521	5,847	11,177	9,412
FCFE	(3,333)	5,625	(2,178)	3,292	1,598
OCF/EBITDA (%)	82.5	109.3	52.5	58.2	45.9
FCFE/PAT (%)	98.6	(1,684.1)	(191.9)	61.9	24.4
FCFF/NOPLAT (%)	47.6	307.2	81.5	112.4	85.7

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	980	980	980	980	980
Reserves & Surplus	72,319	72,254	73,389	78,706	85,263
Net worth	73,299	73,234	74,369	79,686	86,243
Minority interests	(7)	(3)	(3)	(3)	(3)
Deferred tax liability (net)	(4,735)	(4,881)	(4,881)	(4,881)	(4,881)
Total debt	80,519	83,035	82,694	83,024	83,381
Total liabilities & equity	1,49,076	1,51,385	1,52,178	1,57,826	1,64,740
Net tangible fixed assets	29,432	32,227	36,527	40,327	43,827
Net intangible assets	1,480	1,377	1,652	1,818	1,999
Net ROU assets	53,746	53,746	53,746	53,746	53,746
Capital WIP	2,473	2,464	2,710	2,981	3,280
Goodwill	57,428	57,431	57,431	57,431	57,431
Investments [JV/Associates]	2,312	161	161	161	161
Cash & equivalents	3,616	4,038	1,518	5,141	7,095
Current assets (ex-cash)	9,510	11,852	11,961	13,442	14,487
Current Liab. & Prov.	10,922	11,910	13,528	17,221	17,287
NWC (ex-cash)	(1,411)	(58)	(1,567)	(3,779)	(2,799)
Total assets	1,49,076	1,51,385	1,52,179	1,57,826	1,64,740
Net debt	76,903	78,997	81,176	77,883	76,285
Capital employed	1,49,076	1,51,385	1,52,178	1,57,826	1,64,740
Invested capital	1,40,674	1,44,723	1,47,789	1,49,543	1,54,204
BVPS (Rs)	1,127.2	747.5	759.1	813.4	880.3
Net Debt/Equity (x)	1.0	1.1	1.1	1.0	0.9
Net Debt/EBITDA (x)	7.3	4.4	4.0	2.9	2.6
Interest coverage (x)	1.5	1.1	0.9	0.5	0.5
RoCE (%)	3.6	5.0	6.1	9.7	10.3

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	(28.3)	(418.3)	123.1	26.3	21.3
P/CE(x)	21.8	11.8	10.1	7.5	6.6
P/B (x)	1.3	1.9	1.9	1.8	1.6
EV/Sales (x)	4.5	3.6	3.4	2.9	2.6
EV/EBITDA (x)	16.2	12.1	10.9	8.2	7.4
EV/EBIT(x)	57.7	37.0	28.9	16.4	14.7
EV/IC (x)	1.2	1.5	1.5	1.5	1.4
FCFF yield (%)	1.4	6.2	2.6	5.1	4.4
FCFE yield (%)	(3.6)	4.0	(1.6)	2.4	1.1
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0
DuPont-RoE split					
Net profit margin (%)	(8.7)	(0.5)	1.8	7.0	7.8
Total asset turnover (x)	0.4	0.4	0.4	0.5	0.5
Assets/Equity (x)	2.4	2.1	2.1	2.0	1.9
RoE (%)	(7.5)	(0.5)	1.5	6.9	7.9
DuPont-RoIC					
NOPLAT margin (%)	12.9	7.2	11.1	13.1	13.1
IC turnover (x)	0.4	0.4	0.4	0.5	0.6
RoIC (%)	5.0	3.1	4.9	6.7	7.2
Operating metrics					
Core NWC days	(13.7)	(0.3)	(8.9)	(18.2)	(12.2)
Total NWC days	(13.7)	(0.3)	(8.9)	(18.2)	(12.2)
Fixed asset turnover	0.3	0.3	0.3	0.4	0.4
Opex-to-revenue (%)	50.2	47.3	45.4	41.6	41.8

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/11/2024 05:34 PM


Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
20-Jun-24	1,384	1,650	Buy	Pulkit Chawla
14-May-24	1,297	1,650	Buy	Pulkit Chawla
31-Jan-24	1,455	1,900	Buy	Pulkit Chawla
30-Nov-23	1,718	2,060	Buy	Pulkit Chawla
19-Oct-23	1,745	2,060	Buy	Pulkit Chawla
01-Aug-23	1,565	1,820	Buy	Pulkit Chawla
25-Jul-23	1,484	1,700	Buy	Pulkit Chawla
16-May-23	1,435	1,700	Buy	Pulkit Chawla
19-Jan-23	1,678	2,050	Buy	Pulkit Chawla

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 22, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of July 22, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 22, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.